IPS: Position Statement on Use of Buprenorphine for treatment for Opioid Dependence

Sep 25, 2019IPS Secretariat, Position Statement

The Indian Psychiatric Society recognizes that Opioid Dependence is a significant public health challenge in India, as reported by the Government of India in its recent report – Magnitude of Substance Use in India.

The IPS also agrees with World Health Organization (WHO), United Nations Office on Drugs and Crime (UNODC), International Narcotics Control Board (INCB) and many other International and National agencies; which have recommended long-term treatment with opioid agonists like Buprenorphine as the most effective treatment option including for patients in a developing country like India.

IPS will encourage, guide and facilitate members and other treatment providers in India to provide evidence based treatment, with procedures fully compliant with the laws and policies, through various means including through educational / professional developmental activities as well as through tools like practice guidelines, treatment guidelines and standard procedures.



The IPS Archive

All notices, announcement and events of the IPS are now archived for future reference and are availabe in a searchable format for registered members of the society.